Anavex Life Sciences Corp is recruiting patients for their study of ANAVEX2-73 in Rett syndrome patients in British Columbia Children’s Hospital in Vancouver and Alberta Children’s Hospital in Calgary. The study is the first ever clinical trial for Rett syndrome in the Canada.

This is a 12-week study of ANAVEX2-73, a liquid medication administered by mouth, for the treatment of patients with Rett syndrome between 5-17 years of age. The study is randomized, meaning 2 out of 3 participants will receive the study drug and 1 out of 3 will receive placebo. The placebo is an inactive liquid solution that looks and tastes just like the study medication but has no effects. The study involves 4 in-person visits at the clinical site, and 4 phone calls. Participants that complete the trial will be offered the option to enrol in a 48-week Open Label Extension, where all participants will receive the active study drug (not placebo). Study visits will include collection of blood and urine, ECGs (measures electrical activity of the heart), physical examinations and questionnaires completed by the patient’s caregiver. Travel expenses related to visits, such as flights, mileage and food, will be reimbursed by the study.

If you are interested in participating and would like to be added to the contact list please email, Sabrina Millson at smillson@rett.ca.

Include the following details in your email:

• Name
• Province
• Contact number
• Love one’s name and date of birth
• Vaccination status:
• 1st vaccine date and type
• 2nd vaccine date and type

For more information on the study, including full inclusion and exclusion criteria, please visit ClinicalTrials.gov:

https://clinicaltrials.gov/ct2/show/NCT04304482